Page last updated: 2024-11-13

methylprednisolone suleptanate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methylprednisolone suleptanate: prodrug of methylprednisolone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

methylprednisolone suleptanate : An organic sodium salt that is the monosodium salt of methylprednisolone 21-suleptanic acid ester. It is a prodrug of methylprednisolone developed by Pharmacia Corp for the treatment of asthma. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID23663977
CHEMBL ID2106453
CHEBI ID135864
SCHEMBL ID43507
MeSH IDM0148521

Synonyms (41)

Synonym
medrosol
methylprednisolone suleptanate
promedrol
u-67590a
sodium 2-[(8-{[(6alpha,11beta)-11,17-dihydroxy-6-methyl-3,20-dioxopregna-1,4-dien-21-yl]oxy}-8-oxooctanoyl)(methyl)amino]ethanesulfonate
90350-40-6
methylprednisolone suleptanate (usan/inn)
D05002
methylprednisolone suleptanate sodium salt
methylprednisolone suleptanate [usan:inn]
methylprednisolone 21-(8-(methyl-(2-sulfoethyl)amino)-1,8-dioxooctanoate)
suleptanato de methilprednisolona [spanish]
methylprednisoloni suleptanas [latin]
pnu 67590a
suleptanate de methylprednisolone [french]
u-67,590a
7-(methyl(2-sulfoethyl)carbamoyl)heptanoic acid, c-21-ester with 11beta,17,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione, monosodium salt
u 67590a
pnu-67590a
pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-6-methyl-21-((8-(methyl(2-sulfoethyl)amino)-1,8-dioxooctyl)oxy)-, monosodium salt, (6alpha,11beta)-
sodium 2-[{8-[(11beta,17-dihydroxy-6alpha-methyl-3,20-dioxopregna-1,4-dien-21-yl)oxy]-8-oxooctanoyl}(methyl)amino]ethanesulfonate
suleptanato de metilprednisolona
sodium 2-[{8-[(11beta,17-dihydroxy-6alpha-methyl-3,20-dioxopregna-1,4-dien-21-yl)oxy]-8-oxooctanoyl}(methyl)amino]ethane-1-sulfonate
methylprednisolone suleptanate sodium
CHEBI:135864
methylprednisoloni suleptanas
suleptanate de methylprednisolone
methylprednisolone suleptanate monosodium salt
g6cs53ncvs ,
suleptanato de methilprednisolona
unii-g6cs53ncvs
CHEMBL2106453
methylprednisolone suleptanate [inn]
methylprednisolone suleptanate [usan]
methylprednisolone suleptanate [who-dd]
pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-6-methyl-21-((8-(methyl(2-sulfoethyl)amino)-1,8-dioxooctyl)oxy)-, monosodium salt, (6.alpha.,11.beta.)-
methylprednisolone suleptanate [jan]
SCHEMBL43507
DTXSID7023304
Q27278834
sodium;2-[[8-[2-[(6s,8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-6,10,13-trimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-8-oxooctanoyl]-methylamino]ethanesulfonate

Research Excerpts

Overview

Methylprednisolone suleptanate (Promedrol) is being developed by Pharmacia Corp for the treatment of asthma.

ExcerptReferenceRelevance
"Methylprednisolone suleptanate (Promedrol) is a prodrug of methylprednisolone being developed by Pharmacia Corp (formerly Pharmacia & Upjohn) for the treatment of asthma. "( Methylprednisolone suleptanate Pharmacia Corp.
Paggiaro, P, 2000
)
3.19

Pharmacokinetics

ExcerptReferenceRelevance
" No dependence on time was apparent for any prodrug pharmacokinetic parameter."( Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers.
Della-Coletta, AA; Ferry, JJ; VanderLugt, JT; Weber, DJ, 1994
)
0.49
"Ninety volunteers were included in the pharmacokinetic analysis."( A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma.
Daley-Yates, PT; Parker, TJ; Wood, SA, 1997
)
0.3
" Based on individual Bayesian estimates, the exposure of patients to MP was marginally lower for MP suleptanate although the parameter estimates were not significantly different for half-life (2."( A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma.
Daley-Yates, PT; Parker, TJ; Wood, SA, 1997
)
0.3
"The aim of this study was to establish whether pharmacokinetic differences between two pro-drugs of methylprednisolone (MP) are likely to be of clinical significance."( Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone.
Brooks, CD; Daley-Yates, PT; Gregory, AJ, 1997
)
0.3
" Bioequivalence was assessed by conventional pharmacokinetic analysis, by measuring pharmacodynamic responses plus a novel approach using pharmacokinetic/pharmacodynamic modeling."( Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone.
Brooks, CD; Daley-Yates, PT; Gregory, AJ, 1997
)
0.3
"The MP Cmax was less for MP suleptanate due to a longer absorption halflife of the prodrug from the intramuscular injection site."( Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone.
Brooks, CD; Daley-Yates, PT; Gregory, AJ, 1997
)
0.3
" The use of both pharmacokinetic and pharmacodynamic response data together gives greater confidence in the conclusions compared with those based only on conventional pharmacokinetic bioequivalence analysis."( Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone.
Brooks, CD; Daley-Yates, PT; Gregory, AJ, 1997
)
0.3

Bioavailability

ExcerptReferenceRelevance
" In addition the differences in the pharmacokinetics for the prodrugs resulted in only a small difference in the relative bioavailability of MP for MP suleptanate (0."( A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma.
Daley-Yates, PT; Parker, TJ; Wood, SA, 1997
)
0.3
" The bioavailability of MP was equivalent when based on AUC with a MP suleptanate median 108% of the MP succinate value (90% CI: 102-114%)."( Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone.
Brooks, CD; Daley-Yates, PT; Gregory, AJ, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
"It was concluded that for the multiple dosage regimen used in patients with acute asthma the systemic exposure to MP following dosing with MP suleptanate is similar to that arising from MP succinate."( A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma.
Daley-Yates, PT; Parker, TJ; Wood, SA, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
anti-inflammatory agentAny compound that has anti-inflammatory effects.
glucocorticoid receptor agonistAn agonist that selectively binds to and activates a glucocorticoid receptor.
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
anti-asthmatic drugA drug used to treat asthma.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic sodium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (20.00)18.7374
1990's10 (66.67)18.2507
2000's2 (13.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.66 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (26.67%)5.53%
Reviews1 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]